DMAC News and Press, DiaMedica Therapeutics Inc. From 03/10/21

Productive Type B Pre-IND Meeting with FDA Provides Clarity for Planned Stroke Study Program On Track to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 ReMEDy Phase 2 AIS Stud...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney diseases, today announced it will be presenting a plenary talk at the American Heart Association 2021 Intern...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the Company’s lead asset for the treatment of Ac...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company&...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2020 financial results will be released after the markets close on Wednes...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company’s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reach...

DiaMedica Therapeutics (DMAC) has recently received responses from the FDA following a Type B Pre-IND meeting request, submitted in October 2020 regarding the development plan for its product candidate, DM199, in the treatment of acute ischemic stroke ((AIS)).The Agency agreed with DiaMedica&...

DiaMedica Plans to Submit an Investigational New Drug (IND) Application with to FDA for a Phase 2/3 Study in the First Quarter of 2021 DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND mee...

Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis ACB +19%, Lyra Therapeutics (LYRA) +19%, Tilray TLRY +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%,&#x...